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Abstract
Background: The T-cell inhibitory molecule PD-L1 (B7-H1, CD274) is expressed on tumor cells of a subset of breast
cancer patients. However, the mechanism that regulates PD-L1 expression in this group of patients is still not
well-identified.
Methods: We have used loss and gain of function gene manipulation approach, multi-parametric flow cytometry,
large scale gene expression dataset analysis and immunohistochemistry of breast cancer tissue sections.
Results: Induction of epithelial to mesenchymal transition (EMT) in human mammary epithelial cells upregulated
PD-L1 expression, which was dependent mainly on the activation of the PI3K/AKT pathway. Interestingly, gene
expression signatures available from large cohort of breast tumors showed a significant correlation between EMT score
and the PD-L1 mRNA level (p < 0.001). Strikingly, very strong association (p < 0.0001) was found between PD-L1
expression and claudin-low subset of breast cancer, which is known to have high EMT score. On the protein level,
significant correlation was found between PD-L1 expression and standard markers of EMT (p = 0.005) in 67 breast
cancer patients. Importantly, specific downregulation of PD-L1 in claudin-low breast cancer cells showed signs of EMT
reversal as manifested by CD44 and Vimentin downregulation and CD24 upregulation.
Conclusions: We have demonstrated a bidirectional effect between EMT status and PD-L1 expression especially in
claudin-low subtype of breast cancer cells. Our findings highlights the potential dual benefit of anti-PD-L1 particularly
in this subset of breast cancer patients that will likely benefit more from anti-PD-L1 targeted therapy as well as in
monitoring biological changes upon treatment.
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Background
Breast cancer is the most common cancer affecting women
[1]. In the past, the management of this disease has im-
proved greatly upon patients’ segregation based on their es-
trogen and progesterone receptors expression [2] and later
on by their her2/neu over-expression status [3]. Recently,
the remaining tumors that are negative for estrogen
receptors, progesterone receptors and Her/neu overexpres-
sion are further classified into subtypes (like basal-like and
claudin low) and there is evidence that different subtypes
respond differently to various treatment regimens [4, 5].
Further investigations are needed to develop new therapies
for these emerging subtypes of breast cancer.
PD-L1 (also called B7-H1 and CD274) is a T cell inhibi-
tory molecule that is expressed on antigen presenting cells
(APC) leading to T cell anergy and/or apoptosis upon
ligation to its receptor programmed death-1 (PD-1,
CD279) on T cells [6, 7]. PD-L1 was found to be aberrantly
over-expressed in several malignancies where a strong link
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between its expression in cancer cells and patients’ clinico-
pathological status has been demonstrated (Reviewed in
[8]). Importantly, in many cancer types PD-L1 expression
is associated with worse outcome, suggesting the contribu-
tion of PD-L1 to promote tumor escape from the immune
system [9–12].
We and other have previously demonstrated that PD-L1
expression is associated with triple negative breast cancer
[10, 13–15]. In a subsequent complementary study, we
have shown that tumoral expression of PD-L1 was accom-
panied by the infiltration of regulatory T-cells (T-reg), a
subpopulation of T-cells known to inhibit the proliferation
and cytokine production of effector T-cells [16]. There-
fore, PD-L1 and T-reg can provide an immune suppressive
microenvironment, leading to tumor escape from immune
recognition and promotes tumor growth.
Several mechanisms that regulate PD-L1 expression
in cancer cells have been described, including the pres-
ence of inflammatory mediators like the INF-γ [17]
within the tumor microenvironment, the loss of phos-
phatase and tensin homologue (PTEN) with consequent
phosphatidylinositol-3-OH kinase (PI3K) activation
[18], and promotion of cancer cell proliferation [19].
Nevertheless, many breast cancer cells in vivo and in
vitro constitutively express PD-L1 despite normal
PTEN and in the lack of INF-γ, suggesting that another
mechanism may be involved in regulating this process
in breast cancer cells. Understanding the mechanism of
PD-L1 induction can help in reversing it upon therapy.
Anti-PD-L1 antibody targeting therapy is currently
available and has been shown to be safe and effective in
inducing complete or partial response in several carcin-
omas [20, 21]. Whether anti-PD-L1 blocking antibodies
will be effective in breast cancer or not is not yet
known. However, before trying this therapy the subset
of breast cancer patients who will likely upregulates
this molecule and the mechanism of this upregulation
should be identified.
In this paper, we have demonstrated that PD-L1 expres-
sion is induced upon EMT process and is highly signifi-
cantly associated with claudin-low, a subtype of breast
cancer, known to have EMT features. Importantly, down-
regulating PD-L1 reversed EMT process in a claudin-low
breast cancer cells, strongly suggesting an important role
for PD-L1 targeted therapy in this subset of breast cancer.
Methods and materials
Patient selection and consenting
This study was conducted in accordance with the Helsinki
Declaration and it was approved by the Research Advisory
Council (RAC# 2140–001) of King Faisal Specialist Hospital
and Research Centre (KFSH&RC). Normal human mam-
mary gland tissues were obtained from 2 patients admitted
to KFSH&RC who underwent reduction mammoplasty with
no previous history of breast cancer. Sections from Archived
paraffin embedded Breast cancer samples were obtained
from 67 patients diagnosed with invasive ductal carcinoma
of the breast and were previously described [13, 16]. All pa-
tients signed an informed consent approved by KFSH&RC.
Normal breast tissue processing and cell preparation
Normal breast tissues were digested as previously de-
scribed [19, 22]. Briefly, tissues from reduction mammo-
plasty) were digested in collagenase digestion medium
(Stem Cell Technologies (SCT), Vancouver, Canada) and
agitated at 37 °C overnight and cell suspensions were cen-
trifuged at 800 g for 8 min at 4 °C. Cells were differen-
tially centrifuged at 120 g for 2 min at 4 °C to enrich
for epithelial cells. The epithelial-enriched pellet was
further digested with accutase (SCT) at 37 °C (30–60
min) and were cultured as previously described [23].
The supernatant (mesenchymal-enriched fraction) were
centrifuged at 450 g for 8 min, then cultured.
Cell culture, transfection and selection
The Breast cancer cell lines MDA-MB-231 and MCF-7
(ATCC) were maintained in DMEM (Sigma) supplemented
with fetal bovine serum (FBS, Invitrogen) and antibiotics
and antimycotics (ABM, Invitrogen). Normal breast cell
lines: MCF-12A and MCF10A (ATCC) were cultured in
universal medium composed of DMEM/F12 medium sup-
plemented with 10 μg/mL insulin, 20 ng/mL epidermal
growth factor (EGF), 500 ng/mL hydrocortisone (all from
Sigma) and 100 ng/mL cholera Toxin (LIST Biological
Laboratories, Surrey, United Kingdom), 5 % horse serum
(Invitrogen) and 1 % ABM. All established cell lines were
used within 6 months of purchase from ATCC.
Primary cells were selected from overnight digested nor-
mal mammary tissue (see above). Primary luminal cells
were further isolated based on their Ep-CAM positivity
using MACS (Miltenyi Biotec, Germany) cell separation
system. HMLE cell line were generated by transecting
primary luminal cells at passage 1–3 sequentially with len-
tiviruses expressing SV40 (small and long T antigen) and
h-tert (both from ABMgood, Canada). Both primary lu-
minal cells and immortalized luminal cells (HMLE) were
propagated in serum free WIT-P medium (Stemgent,
Cambridge, USA) while primary mesenchymal cells were
cultured in DMEM/F12 supplemented with 10 % FBS.
PD-L1 were downregulated using specific Sh-RNA to
PD-L1 (in a retroviral pGFP-V-RS vector from Origene).
Other specific Sh-RNA were used also for confirmation
(in a lentiviral TRIPZ commercially available vector,
which is activated only in the presence of doxycycline
(1 μg/mL). Selection for PD-L1 Sh-RNA (Sh-PD-L1)
transfected cells were made using puromycin (1 μg/mL).
PD-L1 expression in T-47D was induced by transfecting
cells with PD-L1 ORF (pCMV6-AC-GFP vector from
Alsuliman et al. Molecular Cancer  (2015) 14:149 Page 2 of 13
Origene) and the selection for PD-L1 ORF transfected
cells were made using G418 (500 μg/mL).
EMT was induced using TGF-β1 (2.5 ng/mL, R&D sys-
tems) with daily medium exchange using freshly thawed
TGF-β 1 aliquots. TNF-α, IL-6 and EGF were used at a
concentration of 100 ng/mL. Major pathways involved in
EMT induction were tested on MCF-12A cells using the
general PI3K/AKT pathway inhibitor LY294002 (20 μM),
the MEK/ERK inhibitor U0126 (10 μM), the SMAD in-
hibitor SiS3 (5 μM) and the NF-kB inhibitor Bay 11-7082
(2.5 μM), all from Millipore.
Flow cytometry
Cells were incubated for 30 min on ice with directly
labeled antibodies. Cells were then washed with PBS
followed by fixation in 0.5 % paraformaldehyde in PBS.
Data were acquired using an LSR II flow cytometer
using BD FACSDiva operating software. Positive staining
was considered based on the negativity of an isotype
control. A minimum of 10,000 events were recorded
for all samples.
Immunohistochemistry
Immunohistochemistry for vimentin and E-cadherin were
done on formalin-fixed, paraffin-embedded tissue of previ-
ously described breast cancer samples [13, 16]. Vimentin
was detected using ready-to-use mouse anti-human vimen-
tin antibody from Ventana (Cat# 790-2917) and were
stained using automated staining platform (Ventana). Im-
munohistochemical staining of E-cadherin was done
manually using rabbit anti E-cadherin antibody (clone
EP00y) overnight at a dilution of 1:500. Envision +
polymer (ready to use; Dako) was used as a secondary
antibody. Color was developed with 3,3′-diaminoben-
zidine (DAB) and instant hematoxylin (Shandon) was
used for counterstaining.
Expression analysis of human breast tumor microarray
datasets
The first set of samples were from GSE18864 (n = 84) that
contains gene expression data from 84 breast cancer pa-
tients, 38 of which were triple negative breast cancer
(TNBC), obtained using Affymetrix’s one-channel micro-
array, namely, GeneChip® Human Genome U133 Plus 2.0
Arrays. The data was downloaded from Gene Expression
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/). The
second set of samples analyzed consisted of mRNA ex-
pression profiling of breast invasive carcinoma samples
(n = 530) performed using Agilent G450A_07 arrays from
Cancer Genome Atlas (TCGA) project (http://cancergen-
ome.nih.gov) [24], and TCGA level 3, the most highly proc-
essed data were downloaded in accordance with TCGA
Data Access Policies (https://tcga-data.nci.nih.gov/tcga/).
For each dataset, an EMT score for each sample was cal-
culated as the average expression of genes up-regulated in
EMT minus the average expression of genes down-
regulated in EMT using the 17 EMT signature genes
(ZEB1, ZEB2, Snai1, Snail2, Twist1, Twist2, FOXC2, VIM,
FN1, SOX10, MMP2, MMP3, CDH1, CLDN3, CLDN4,
CLDN7 and DSP). The claudin-low (CL) scores for each
sample were calculated based on mRNA expression of
claudin-low gene signature (1604 genes from Prat el [5]).
CL score was calculated as the average expression of genes
up-regulated in CL subtype of breast cancer minus that
are down-regulated in CL subtype.
Statistical analysis
Significance in expression or mammosphere formation
was determined by Student’s t-test. Comparison of cat-
egories within a given characteristic was carried out
with the χ2 test, if any of the expected frequencies was
less than five, the Fisher’s exact test was used. Two-sided
P-value of < 0.05 was considered statistically significant.
Statistical analyses were performed using MATLAB soft-
ware packages (Mathworks, Natick, MA, USA), JMP®
Pro11, GraphPad Software, Inc and PARTEK Genomics
Suite (Partek Inc, St. Lois, MO, USA).
Results
PD-L1 expression level is associated with the mesenchymal
features of normal and malignant breast
To understand the mechanism that regulates PD-L1
constitutive expression in some native PTEN expressing
breast cancer cells and in the absence of INF-γ we
screened breast cancer cell lines available in our labora-
tory according to their level of PD-L1 expression. Most
of the PD-L1 positive cell lines had mesenchymal
features, while PD-L1 negative cell lines demonstrated
luminal characteristics (Fig. 1a). The correlation between
PD-L1 expression and mesenchymal features in breast
cancer cell lines prompted us to investigate if such rela-
tionship is physiologically relevant to the normal human
breast. Therefore, we determined the level of PD-L1 in
the different subpopulations of unmanipulated, uncul-
tured segregated human mammary gland cells. Using
multi-parametric flow cytometry, which we have previ-
ously established [22], PD-L1 positive cells could be
identified as Ep-CAMneg/CD49fneg, CD44high/CD24low,
CD90high/CD31neg, a typical phenotype for the mesen-
chymal fraction of human breast cells (Fig. 1b, detailed
gating is available in Additional file 1: Figure S1). We
have further isolated the epithelial (luminal and myoe-
pithelial) and mesenchymal fractions of the human
breast cells and cultured them in vitro for 1–2 passages.
In consistence with their in vivo phenotype, mesenchy-
mal cells in culture (in vitro) had the highest level of
PD-L1 expression, while luminal cells had the lowest
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level of expression (Fig. 1c). The above data show an as-
sociation between mesenchymal features and the level of
PD-L1 expression in normal human breast cells. To-
gether, our data showed that PD-L1 expression level is
associated with the mesenchymal features of normal and
malignant breast cells.
In order to demonstrate the effect of mesenchymal
status on PD-L1 expression, we induced epithelial to
mesenchymal transition (EMT) using continuous TGF-β1
treatment on three normal cell lines (HMLE, MCF10A and
MCF12A) and a primary luminal epithelial cells and mea-
sured PD-L1 protein expression using flow cytometry. In-
duction of EMT reproducibly and significantly upregulated
PD-L1 up to 3 folds in all tested normal cells (Fig. 2a & b,
p < 0.001). EMT-mediated PD-L1 upregulation was parallel
to upregulation of CD44 and the down regulation of
CD24 surface markers (Fig. 2c) and morphological
changes from cobble-stone tightly arranged cells (epi-
thelial-like) to spindle shaped widely distributed (mes-
enchymal-like) cells (Fig. 2d). The effect of TGF-β1
induced PD-L1 was not limited to normal breast cells
as breast cancer cell lines also showed similar results
albeit with much less efficiency than normal cells
(Additional file 1: Figure S2A).
To confirm that the upregulation of PD-L1 expres-
sion is due to the EMT process and not TGF-β1 itself,
we induced EMT by transfection with H-RAS onco-
gene, or treatment with IL-6, TNF-α, or EGF. Transfec-
tion of MCF-12A normal breast cells with H-RAS
upregulated PD-L1 expression up to 2 folds. Similarly
treatment with IL-6, TNF-α, and EGF upregulated PD-
L1 (Additional file 1: Figure S2B). The above data show
that the EMT process upregulates PD-L1 expression in
normal and malignant human breast epithelial cells.
Upregulation of PD-L1 is dependent on the PI3K/AKT and
MEK/ERK pathways activation
To understand the mechanism of EMT-mediated PD-
L1 upregulation in breast cells, we have used MCF-12A
normal breast cells as they were the most efficient in
undergoing an EMT. We exposed MCF-12A to con-
tinuous TGF-β1 treatment in the presence or absence
of specific inhibitors of the 4 main pathways known to
be involved in EMT induction [25, 26]. Among all
tested PI3K, ERK, SMAD, and NF-κB pathway blockers,
the PI3K/AKT pathway inhibitor (LY294002) was the
most successful in abolishing the up-regulation of PD-
L1 protein expression upon EMT induction as mea-
sured by flow cytometry (Fig. 3a), and to a lesser extent
MEK/ERK inhibitor (U0126). On the other hand, NF-
κB blocker (Bay 11–8072) and SMAD 2/3 inhibitor
(SiS3) had no or very minor effect on PD-L1 upregulation
(Fig. 3a & b).
Gene expression signatures (GES) show tight association
between PD-L1, EMT and claudin low breast cancer
To expand our in vitro findings and to test the associ-
ation of EMT status with PD-L1 mRNA expression in
breast cancer patients, we used large number of breast
cancer patients’ gene expression profiling data from pub-
lically available databases. We calculated the EMT score
of each breast cancer sample using EMT gene signature
(Materials and Methods) and correlated it with the level
of PD-L1 [27]. We tested this correlation in GSE18864
dataset of breast cancer patients that was profiled on Affy-
metrix one-color arrays. Although the number of patients
within this dataset was relatively small (n = 84), there
was significant association between EMT status and
PD-L1 expression (r = 0.24, p value = 0.026, Additional
file 1: Figure S3A).
Previous findings showed significant correlation be-
tween PD-L1 expression and triple negative breast
cancer (TNBC) [15], which has recently been further
classified into different subtypes including basal-like
and claudin-low. Among all subtypes, claudin-low breast
cancer has the highest association with EMT status [5, 28,
29]. Therefore, we tested the correlation between PD-L1
expression with claudin-low subtype. Using the claudin-low
gene signature, we calculated claudin-low score for
each patient’s sample (as described in Materials and
Methods). PD-L1 expression significantly correlated (r =
0.58, p value = 7.05x10−9) with claudin-low subtype
(Additional file 1: Figure S3B). Among the 84 patients
in GSE18864 dataset, 38 patients were TNBC. Interestingly,
the statistical significance between EMT score and PD-L1
expression was higher (r = 0.42, p value = 0.0095) when
analysis was limited to TNBC patients (Additional file 1:
Figure S3C). Similarly, there was highly significant correl-
ation between claudin-low and PD-L1 expression within
TNBC patients (r = 0.73, p value = 2.65x10−7, Additional file
1: Figure S3D). These data show significant correlation
(See figure on previous page.)
Fig. 1 PD-L1 is associated with mesenchymal status of normal and malignant breast. a Normal and breast cancer established cell lines grouped
into luminal-like, basal/mesenchymal-like breast cancer cells and others including normal breast cell lines. b Representative flow cytometry dot
plots showing the phenotype of PD-L1 positive segregated normal human breast cells as measured by Ep-CAM/CD49f, CD44/CD24 and CD90/
CD31 expression and as analyzed by multi-parametric flow cytometry following serial gating to remove debris, dead and hematopoietic cells.
c Representative flow cytometry histogram showing the level of PD-L1 expression in primary cultured epithelial (luminal and myoepithelial) and
mesenchymal cells
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between the PD-L1 expression level and the EMT status of
breast cancer patients in the GSE18864 dataset.
We further used another well-known dataset, which uses
a different array platform (Agilent) and with much larger
patient size, the TCGA breast cancer dataset (n = 530 pa-
tients), to validate our findings on the association of PD-L1
expression with EMT status. In this large dataset there
was a highly significant correlation (r = 0.14, p = 0.0009)
between PD-L1 expression and EMT status (Fig. 4a). In
fact, certain EMT inducing transcription factors (ZEB2,
SNAI1, ZEB1) individually correlated with PD-L1
expression, with the most significant correlation (r =
0.42, p = 1.9x10−24) with ZEB2 (Fig. 4b). More interest-
ingly, there was an extremely significant correlation (r
= 0.61, p = 8x10−54) between claudin-low subset of
breast cancer and PD-L1 expression level (Fig. 4 c&d).
This demonstrates that PD-L1 is highly associated with
EMT status and claudin-low subset of breast cancer in
TCGA dataset of breast cancer patients.
Using multiple datasets of breast cancer patients, we
have demonstrated that PD-L1 correlates with EMT sta-
tus of breast cancer patients and molecular subtypes of
Fig. 3 PI3K and ERK inhibitors abrogates EMT-mediated PD-L1 upregulation a EMT-mediated PD-L1 upregulation in MCF-12A cells in the
presence or absence of major EMT pathway inhibitors, calculated as a percentage of the level of PD-L1 in untreated cells as per the equation %
upregulation ¼ PDL1 expression after TGF1 treatment−PDL1 before TGF1 treatmentPDL1 before TGF1 treatment and without any blocker  100 b Representative flow cytometry histogram of PD-L1 before and
after TGF-β1 treatment in the presence or absence of EMT inhibitors
(See figure on previous page.)
Fig. 2 Epithelial to mesenchymal transition (EMT) upregulates PD-L1 in the human breast cells. a Bar graphs showing the expression level of PD-L1 as
measured by flow cytometry in four normal breast cells before and after EMT induction using continuous treatment with TGF-β1 (2.5 ng/mL) for 7 days
for MCF-12A and MCF10A cells and 14 days for primary luminal and HMLE cells. Bars represent the means of 3 independent experiments ± standard
deviation (SD) b Representative flow cytometry histograms for PD-L1 and c a typical image for cells before and after EMT induction. d representative
flow cytometry histograms showing the expression of intracellular vimentin/E-cadherin molecules and dot blots of CD44/CD24 cell surface markers of
MCF12A after EMT induction using TGF-β1 (2.5 ng/mL)
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breast cancer showing signs of EMT, further supports
for the tight relationship between PD-L1 and EMT in
breast cancer.
PD-L1 expression on the protein level is associated with
EMT status of tumor cells in breast cancer patients
The above PD-L1 expression analysis on breast cancer
patients was performed using mRNA expression, which
does not always correlate with protein expression.
Therefore, we tested the association between the PD-L1
protein level and EMT status in breast cancer patients
using 67 breast cancer patients with previously known
PD-L1 status [16]. The EMT status of breast cancer cells
was assessed in by staining previously archived paraffin
embedded sections with antibodies against vimentin and
E-cadherin (Additional file 1: Figure S4A&B). PD-L1 ex-
pression significantly associated (p = 0.014) with vimen-
tin expression in breast cancer cells (Table 1). Similarly,
Fig. 4 Correlation of PD-L1 expression, EMT and claudin-low subtype of breast cancer using TCGA gene expression dataset. Gene expression dataset
from the TCGA breast cancer samples (total of 530 patients) showing the correlation of PD-L1 expression with EMT score and claudin-low breast cancer
A&C). Heat map showing mRNA expression level of mesenchymal and Epithelial genes in addition to top 100 claudin-low gene expression signature
(up- or down-regulated in CL). The samples in the data are arranged according to their EMT score (a) or according to their claudin-low score (c) and
compared with PD-L1 expression, as indicated with the arrow at the top. B&D) Scatter plot of PD-L1 mRNA expression level correlates significantly that
of with ZEB2 (b) or claudin-low score (d) in TCGA breast cancer samples (p < 0.0001)
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there was significant correlation with E-cadherin down-
regulation (p = 0.039). Interestingly, when the data is
stratified to patients showing simultaneous vimentin up-
regulation and E-cadherin downregulation, the statistical
correlation with PD-L1 expression was much more sig-
nificant (p = 0.005). These findings demonstrate that
the PD-L1 protein level correlates well with EMT status
of tumor cells in breast cancer patients.
Manipulation of PD-L1 modulates EMT status of breast
cancer cells
The above data show that PD-L1 is upregulated upon
EMT and is predominantly expressed in claudin-low
breast cancer. However, it is unknown if the PD-L1 mol-
ecule itself has any role in the EMT process. In order to
address this, we have used specific ShRNA to downregu-
late PD-L1 in the claudin-low breast cancer cell line
(MDA-MB-231), which expresses high level of PD-L1.
Interestingly, downregulation of PD-L1 in MDA-MB-
231 cells downregulated CD44 by 30 %, and vimentin by
10 % while it upregulated CD24 by 5 % (Fig. 5a & b).
Using the combination of CD44 and CD24 shows that
PD-L1 downregulation decreased the fraction of MDA-
MB-231 cells with typical mesenchymal phenotype
CD44high/CD24low/neg and increased the rare epithelial-
like fraction in MDA-MB-231 cells by up to 3 folds. We
were able to confirm our findings using another different
Sh-RNA that is under the control of doxycyline and we
got similar results only when doxycycline was added
confirming the specific effect of PD-L1 downregulation
(Additional file 1: Figure S5). To further examine the
role of PD-L1 on the EMT process in other subtypes of
breast cancer we induced the expression of PD-L1 in
T47D luminal-like breast cancer cell line which is
typically negative for PD-L1. Overexpression of the PD-
L1 molecule downregulated CD24 by 70 % and
downregulated E-Cadherin expression by 16 %. However,
there was only slight decrease in CD44 expression
(Fig. 5c). Therefore, PD-L1 manipulation in breast can-
cer cells modulates the EMT status of these cells.
Discussion
PD-L1 expression in breast cancer cells is significantly
associated with hormone receptor negativity. However,
the consequence of this association and the underlying
mechanism has not been investigated before. In this
study we have demonstrated that the pro-metastatic
process EMT induces the expression of PD-L1. Further-
more, we have identified an association between PD-L1
expression and claudin-low breast cancer, a subset of
breast cancer patients known to have high EMT score.
Interestingly, we have shown that PD-L1 expression is
important for the maintenance of the EMT status in this
subtype of breast cancer cells.
EMT is a biological process whereby epithelial cells lose
their cell-to-cell junctions and gain features of mesenchy-
mal cells like higher migration, and invasion. This process
is paralleled by a change in some of the markers like
CD44, CD24, vimentin and E-cadherin. Mesenchymal
cells have a CD44high/CD24low, vimentinpos and E-
cadherinneg phenotype, while epithelial cells normally
have CD24high, vimentinneg and E-Cadherinpos phenotype.
During the EMT process epithelial cells acquire the
CD44high/CD24low phenotype, up-regulate vimentin and
down-regulate E-Cadherin.
We and others have reported several mechanisms that
regulate PD-L1 expression in breast cancer cells. These
include the presence of inflammatory mediators within
the tumor microenvironment [17], the loss of phosphat-
ase and tensin homologue (PTEN), a negative regulator
of PI3K activation [18], and cancer cell proliferation
[19]. However, none of the previously reported mecha-
nisms explained the constitutive expression of PD-L1 in
cancer cells that lacks PTEN mutation/deletion and in the
absence of inflammatory mediators. We have shown here
that the EMT process induces PD-L1 expression and that
the expression of this molecule participates in the main-
tenance of EMT status in the breast cancer cells.
The main signaling pathways involved in the EMT
process are PI3K/AKT, SMAD, NF-κB and ERK/MAPK
pathways (Reviewed in [25]). It is believed that the differ-
ent features of EMT involve different pathways. For ex-
ample, PI3K/AKT is important for the EMT-related
enhanced migration of cells [30], while NF-κB is involved
in the EMT induced chemoresistance of tumor cells [31].
Importantly, we have shown that EMT-induced upregula-
tion of PD-L1 is PI3K/AKT-and ERK/MEK-dependent.
Although both pathways were important for the up-
regulation of PD-L1, the involvement of PI3K/AKT path-
way was more important. This finding is consistent with
Table 1 Association between PD-L1 and markers of EMT in 67
breast cancer patients
PD-L1 Expression *P value
+ -
E-Cadherin
Down-regulated (≤70 %) 9 (47)a 10 (53) 0.039
Positive (> 70 %) 10 (21) 38 (79)
Vimentin
Up-regulated (> 5 %) 10 (53) 9 (47) 0.014
Negative (<5 %) 9 (19) 39 (81)
E-Cadherin-down/Vimentin-up
Present 6 (75) 2(25) 0.005
Absent 13 (22) 46 (78)
Abbreviations: (+ and -) are number of positive and negative patients,
aNumbers between brackets are the percentages of patients, *P values
(by Fisher’s exact test) in bold represent a significant data
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previous findings showing critical role of the PI3K/AKT
pathway in the expression of PD-L1 in breast cancer [32].
Similarly, the involvement of the ERK/MEK pathway in
PD-L1 expression has been previously reported [33].
The induction of EMT in breast cancer cells is patho-
logically relevant. It is highly associated with claudin-low
breast cancer which has received a lot of attention
recently. Interestingly, this subset of breast cancer is as-
sociated with a high degree of immune cell infiltrate and
bad prognosis, suggesting the presence of an ineffective
anti tumor immunity. The exact immune suppressive
molecules associated with this subset of breast cancer is
not well-described. Interestingly, induction of EMT in
breast cancer cells using Snail, an EMT transcription
factor, promoted the escape of breast cancer cells from
T-cell mediated lysis by CD8+ cytotoxic T cells [34].
This finding supports the role of EMT in the immune
escape of breast cancer cells. We have shown for the
first time that claudin-low subtype of breast cancer is as-
sociated with high PD-L1 expression, which is likely due
to EMT, and that can lead to immune suppression and/
or activation of an ineffective immune response. During
the preparation of this manuscript, a novel data emerged
showing similar findings in lung cancer, suggesting that
our novel finding in breast cancer is a broad phenomena
that might include many carcinomas [27].
Recently, a targeted therapy for PD-L1 became available
and it has shown great success in several types of carcin-
omas like non-small cell lung cancer and melanoma. These
trials are encouraging to try this therapy against breast car-
cinomas. However, it is important to choose the appropri-
ate patients who would likely benefit from this treatment.
Our findings suggest that claudin-low breast cancer pa-
tients who express high level of this gene, have EMT and
thus possibly can benefit from the reversal of the immune
process into a more favorable cytotoxic type. Recent data
showed that patients who would likely benefit from PD-L1
therapy typically have tumor infiltrated with exhausted
CD8+ T-cells and overexpress PD-L1 [35, 36]. Given that
claudin-low breast cancer is associated with high expres-
sion of PD-L1 and immune cell infiltration, PD-L1 block-
ade will likely reverse the immune suppression and
subsequently leads to activation of anti-tumor activity.
Importantly, there is an established link between EMT
and the gain of stem cell functions in breast cancer [37].
These functions include the ability to grow in anchorage
independent conditions and to reestablish tumors in
mice models even when a very small number of cells are
transplanted. Therefore, it is possible that by targeting
PD-L1 we can target these cells, which constitute the
main seed for tumor initiation and maintenance. To this
end, further investigations are required.
Conclusion
In conclusion the present data show that EMT status of
breast cancer cells is an important regulator of PD-L1
constitutive expression in breast cancer cells. In addition,
we have shown that PD-L1 expression is tightly associated
with claudin-low breast cancer and that targeting PD-L1
expression would reverse EMT in this type of cells.
Additional file
Additional file 1: Figure S1. Gating strategy to analyze PD-L1 expression
in breast cells using multicolor flow cytometry (9 colors). Single isolated cell
from normal breast tissue obtained from reduction mammoplasty were
analyzed with sequential gating. Forward scatter (FSC) and side scatter (SSC)
to extract cells from debris. DAPI positive cells were excluded to gate on
viable cells only. CD45 were used to exclude hematopoietic cells followed by
gating on PD-L1 positive cells. PD-L1 positive cells were further analyzed for
Ep-CAM/CD49f, CD44/CD24 and CD90/CD31 expression levels. Figure S2.
Upregulation of PD-L1 upon EMT induction in both normal and breast cancer
cells. A) Flow cytometry histogram showing the expression level of PD-L1
molecule before and after 3 days of continuous TGF-β1 treatment in normal
(MCF10A and MCF12A) and breast cancer (SK-BR-3, Hs578T and BT-594) cells.
B) PD-L1 expression before and after EMT induction by transfection with
H-RAS in MCF-12A cells as measured by flow cytometry. Figure S3. PD-L1
expression (mRNA) in breast cancer dataset correlated with EMT score and
Claudin-low breast cancer. Gene expression dataset from the GSE18864 (total
of 84 patients) showing the correlation of PD-L1 expression with EMT score
(A&C) and Claudin-low breast cancer subtype (B&D). Heatmap shows mRNA
expression level of mesenchymal and epithelial genes (A&C) in addition to
top 100 (up- or down-regulated) claudin-low gene signature (B&D) from
patients arranged according to their EMT score (A&C) or claudin-low score
(B&D). The data in A&B are from the whole GSE18864 dataset (n= 84) while
in C&D it is limited to TNBC patients (n = 38) only. Figure S4. PD-L1
expression correlates with Vimentin upregulation and E-cadherin
downregulation. A) Representative images of paraffin embedded section of
breast cancer stained with E-cadherin or vimentin and examined under light
microscope B) Representative images of normal duct in one of these sections
stained with E-cadherin or vimentin showing typical staining pattern.
(PPTX 2880 kb)
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Fig. 5 Manipulation of PD-L1 modulates EMT status of breast cancer cells. EMT status determined by the expression of CD44, CD24, and vimentin or
CD44/CD24 combination as measured by flow cytometry following PD-L1 knockdown using specific Sh-RNA mesenchymal-like (MDA-MB-231) breast
cancer cells (a & b). or PD-L1 overexpression by transfection with PD-L1 ORF in the luminal-like (T47D) breast cancer cells (c). Bars in a represent the
means of 3 three different clones and 3 different experiments ± standard deviation (n = 9) while histograms in b & c are representative of one of the
experiments. Lines in each histograms represent threshold of positivity as determined by isotype control except of CD44 in MDA-MB-231 cells where it
is an arbitrary line to show CD44high status
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